BIOTRICITY INC.

BTCY

CIK 0001630113 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$4M
↑+10.2% +$369Kvs FY2024 (Q4)
Operating Income
$441K
Gross Profit
$3M
↑+17.6% +$488Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
43/100
  • Profitability
    5ROIC 6.1% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.22 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    100Asset Turnover 2.38x (1.0+ = capital-efficient)
  • Growth
    51Revenue YoY +10.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 11.1% · trend +24.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Dividends paid (TTM)
cash returned to holders
Stock-based comp (TTM)
$1M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$6M
everything owned
Total liabilities
$38M
everything owed
Stockholders' equity
$-34M
shareholder claim

Recent performance · 51 quarters

Revenue↑+10.2% +$369K
$4M
Net Income↑+41.7% +$512K
$-717K
Free Cash Flow
$416K
Operating Margin↑+15.7pts
11.1%

Drill down